Different treatment outcomes with different formulations of clobetasol propionate 0.05% for the treatment of plaque psoriasis

Journal of Dermatological Treatment

Volumn 19, Issue 6, 2008, Pages 354-359

  Mraz, Serena ^a   Leonardi, Craig ^b   Colón, Luz E ^c   Johnson, Lori A ^c  

^a Solano Clinical Research   (United States)

^b Central Dermatology   (United States)

^c Galderma Laboratories   (United States)

Author keywords

Clobetasol propionate; Clobetasol propionate foam; Clobetasol propionate spray; Plaque psoriasis; Topical corticosteroids

Indexed keywords

CLOBETASOL PROPIONATE; CLOBEX; CORTICOSTEROID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY SURFACE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS VULGARIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALIFORNIA; CHEMISTRY, PHARMACEUTICAL; CLOBETASOL; DERMATOLOGIC AGENTS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROSPECTIVE STUDIES; PSORIASIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 56549110741     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630802449104     Document Type: Article

References (19)

1. Van de Kerkhof PC. Consistent control of psoriasis by continuous long-term therapy: The promise of biological treatments. J Eur Acad Dermatol Venereol. 2006;20:639-50.
2. Van de Kerkhof PC, editor. Psoriasis. St Louis, MO: Mosby; 2003.
3. Hradil E, Lindstrom C, Moller H. Intermittent treatment of psoriasis with clobetasol propionate. Acta Derm Venereol. 1978;58:375-7.
4. Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg. 2003;7:185-92.
5. Beutner K, Chakrabarty A, Lemke S, Yu K. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. J Drugs Dermatol. 2006;5:357-60.
6. Katz HI, Hien NT, Prawer SE, Scott JC, Grivna EM. Betamethasone dipropionate in optimized vehicle. Intermittent pulse dosing for extended maintenance treatment of psoriasis. Arch Dermatol. 1987;123:1308-11.
7. Melian EB, Spencer CM, Jarvis B. Clobetasol propionate foam, 0.05%. Am J Clin Dermatol. 2001;2:89-92; discussion 93.
8. Jarratt MT, Clark SD, Savin RC, Swinyer LJ, Safley CF, Brodell RT, Yu K. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis. Cutis. 2006;78:348-54.
9. Menter A. Topical monotherapy with clobetasol propionate spray 0.05% in the cobra trial. Cutis. 2007;80(5 suppl):12-19.
10. Feldman SR, Housman TS. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol. 2003;4:221-4.
11. Housman TS, Mellen BG, Rapp SR, Fleischer AB Jr, Feldman SR. Patients with psoriasis prefer solution and foam vehicles: A quantitative assessment of vehicle preference. Cutis. 2002;70:327-32.
12. Ali SM, Brodell RT, Balkrishnan R, Feldman SR. Poor adherence to treatments: A fundamental principle of dermatology. Arch Dermatol. 2007;143:912-15.
13. Baldwin HE. Tricks for improving compliance with acne therapy. Dermatol Ther. 2006;19:224-36.
14. Lee IA, Maibach HI. Pharmionics in dermatology: A review of topical medication adherence. Am J Clin Dermatol. 2006;7:231-6.
15. Wauters O, Roland I, De la Brassinne M. [Corticosteroids and their vehicle in the treatment of scalp psoriasis.] Rev Med Liege. 2007;62:196-9.
16. Feldman SR, Gelfand JM, Stein Gold L, Jones SD. The role of topical therapy for patients with extensive psoriasis. Cutis. 2007;79(1 suppl 2):18-31.
17. Opmeer BC, Heydendael VM, Deborgie CA, Spuls PI, Bossuyt PM, Bos JD, de Rie MA. Patients with moderate-tosevere plaque psoriasis preferred oral therapies to phototherapies: A preference assessment based on clinical scenarios with trade-off questions. J Clin Epidemiol. 2007;60:696-703.
18. Warino L, Balkrishnan R, Feldman SR. Clobetasol propionate for psoriasis: Are ointments really more potent? J Drugs Dermatol. 2006;5:527-32.
19. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol. 2005;125:659-64.